A Rare Case of Sodium-Glucose Cotransporter-2 Inhibitor-Induced Acute Pancreatitis

Division

Far West

Hospital

MountainView Hospital

Document Type

Case Report

Publication Date

11-24-2023

Keywords

diabetes type 2, gastrointestinal, medication side-effects, medication-induced pancreatitis, sodium-glucose cotransporter-2 (sglt-2) inhibitors

Disciplines

Internal Medicine | Medicine and Health Sciences | Nutritional and Metabolic Diseases

Abstract

Acute pancreatitis is an acute inflammatory process of the pancreas that requires hospital admission and treatment. There are many causes of pancreatitis, the most common being gallstone and alcohol-induced; other reasons include metabolic, infectious, and medication-induced. A new medication that has come to the market is empagliflozin, which is a sodium-glucose cotransporter-2 inhibitor that is common in managing type 2 diabetes mellitus and congestive heart failure. Although generally considered safe and effective, rare adverse effects have been reported. In this case, we present a 67-year-old female patient who presented with severe acute pancreatitis after two weeks of starting empagliflozin to treat her type 2 diabetes. This case report highlights the importance of considering rare adverse events associated with empagliflozin and the need for close monitoring of patients receiving this medication.

Publisher or Conference

Cureus

Link to Full Text

Share

COinS